Compare MGM Resorts International (MGM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Natera Inc. Common Stock — how do they compare? MGM Resorts International trades at $28.73 (market cap $7.40B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 7.7× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 92 Days and Natera Inc. Common Stock for 0 Days on average.
| MGM | NTRA | |
|---|---|---|
Market Cap | $7.40B | $57.03B |
Volume | 3,687,296 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $425.64 |
52-Week Low | $28.96 | $179.42 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $34.70B | $56.18B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $28.96, down 1.23% amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition offer. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal mixed results with Q2 2026 EPS beating expectations but net margins declining to 2.4%. Recent news highlights ongoing M&A discussions, including potential MGM bids for People Inc., creating uncertainty around strategic direction.
Despite near-term headwinds, MGM maintains strong analyst support with 51% buy ratings and a $47.57 consensus target representing 64% upside. Key risks include execution on acquisition strategy, declining profitability margins, and high debt levels. The current valuation at 17.8x P/E appears reasonable if management can stabilize earnings and navigate the evolving casino landscape effectively.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
